Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
Arch Neurol 67:559-563, Prabhakaran,S., et al, 2010
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010
Efficacy of Intra-Arterial Fibrinolysis for Acute Ischemic Stroke: Meta-Analysis of Randomized Controlled Trials
Stroke 41:932-937, Lee,M., et al, 2010
Safety of tPA in Stroke Mimics and Neuroimaging-Negative Cerebral Ischemia
Neurol 74:1340-1345, 1336, Chernyshev,O.Y., et al, 2010
Clinicopath Conf., Progressive Multifocal Leukoencephalopathy
NEJM 362:1431-1437, Case 11-2010, 2010
Is the Diagnosis at Hand?
The Lancet 375:1134, Holmes,M.V., et al, 2010
Ultraearly Thrombolysis in Acute Ischemic Stroke Is Associated with Better Outcome and Lower Mortality
Stroke 41:712-716, Strbian,D., et al, 2010
Drip, Ship, and Retrieve: Cooperative Recanalization Therapy in Acute Basilar Artery Occlusion
Stroke 41:722-726, Pfefferkorn,T., et al, 2010
Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010
Progressive Multifocal Leukoencephalopathy in Individuals with Minimal or Occult Immunosuppression
JNNP 81:247-254, Gheuens,S., et al, 2010
Management of Thrombolysis-Associated Symptomatic Intracerebral Hemorrhage
Arch Neurol 67:965-969, Goldstein,J.N., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Safety of Performing CT Angiography in Stroke Patients Treated With Intravenous Thrombolysis
JNNP 81:783-787, Aulick�,P., et al, 2010
The "Golden Hour" and Acute brain Ischemia: Presenting Features and Lytic Therapy in >30000 Patients Arriving Within 60 Minutes of Stroke Onset
Stroke 41:1431-1439, Saver,J.L., et al, 2010
Critical Vasospasm During Fingolimod (FTY720) Treatment in a Patient With Multiple Sclerosis
Neurol 74:2022-2024, Schwarz,A., et al, 2010
Acyclovir Resistance in Herpes Simplex Encephalitis
Ann Neurol 67:830-833, Schulte,E.C., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Is Thrombolysis Safe in the Elderly? Analysis of a National Database
Stroke 41:2259-2264, Alshekhlee,A.,et al, 2010
Effect of Weekend Compared With Weekday Stroke Admission on Thrombolytic Use, In-Hospital Mortality, Discharge Disposition, Hospital Charges, and Length of Stay in the Nationwide Inpatient Sample Database, 2002 to 2007
Stroke 41:2323-2328, Hoh,B.L.,et al, 2010
An Effective Immunotherapy Regimen for VGKC Antibody-Positive Limbic Encephalitis
JNNP 81:1167-1169, Wong,S.H.,et al, 2010
Coccidioidal Meningitis: Clinical Presentation and Management in the Fluconazole Era
Medicine 89:251-284, Mathisen,G.,et al, 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients
Stroke 41:1996-2000, Abou-Chebl,A.,et al, 2010
Diagnostic Role of Target Lesion on Diffusion-WEighted Imaging, A Case of Cerebral Aspergillosis and Review of the Literature
Neurologist 16:364-367, Finelli,P.F.,et al, 2010
No-Go to Tissue Plasminogen Activator for Transient Ischemic Attack
Stroke 41:3005-3006, 3007, Liebeskind,D.S., 2010
Pro: Intravenous Tissue Plasminogen Activator in Stroke Patients With Rapid, Complete Recovery During Evaluation (Transient Ischemic Attack) and Evidence of Middle Cerebral Artery Occlusion
Stroke 41:3003-3004, 3007, K�hrmann,M. &Schellinger,P.D., 2010
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Neuro-Lyme Disease: MR Imaging Findings
Radiol 253:167-173, Agarwal, R. & Sze, G., 2009
Hyperdense or Pseudohyperdense MCA Sign, A Damocles Sword?
Neurol 72:116-117, Jha,B. & Kothari,M., 2009
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
J Natl Cancer Inst 101:946-958, Armstrong,G.T.,et al, 2009
Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009
Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection
Stroke 40:37772-3776, Engelter,S.,et al, 2009
CNS Complications of Radiotherapy and Chemotherapy
Lancet 374:1639-1651, Soussain,C.,et al, 2009
High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil
Arch Neurol 66:1128-1133, Jacob,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Brainstem Lesions in Diffusion Sequences of MRI Can be Reversible After Arterial Recanalization
Neurol 73:813-815, Vilas,D., 2009